X
Xenothera
Biotech & Life Sciences · Nantes, France · Founded 2014
Developing improved immunological treatments using their glyco-humanized antibody platform MoreLess
Developer of immunosuppressants designed for transplantation and other indications. The company developed a Glyco-humanized antibody platform with embedded technology for the creation of hyperimmune polyclonal sera, enabling the medical community to optimize immunological treatments. Keywords: Pharmaceuticals and BiotechnologyDrug Develop Company, Drug Production, Drug Research, Genetic Engineering, Infectious Disease, Renal Transplantation.
Company overview
Xenothera company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- Nantes, France
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 66.3
Valuation & funding
Xenothera funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jun 2021 | $22M | $88M | MH Innov' · Anaxago · EIC Fund | — |
| EARLY VC✓Equity / VC | Jun 2020 | $3.1M | $12M | Undisclosed | — |
| DEBT✓Debt | Jun 2020 | $2.5M | — | Bpifrance | — |
| EARLY VC✓Equity / VC | Mar 2020 | $0 | — | EIC Fund | — |
| GRANT✓Other financing | Mar 2020 | $2.2M | — | European Innovation Council | — |
| SEED✓Equity / VC | Jul 2017 | Arts et Métiers Business Angels | ↗ | ||
| GRANT✓Other financing | Dec 2016 | European Innovation Council | — | ||
| SEED✓Equity / VC | Jun 2016 | Starquest Capital | — | ||
| SUPPORT PROGRAM✓Other financing | Jul 2014 | Ouest Valorisation | — | ||
| SPINOUT✓Other financing | Jun 2014 | Ouest Valorisation · Nantes University | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | Profit | Margin |
|---|---|---|---|---|
| 2026 | $11K | 0% | −$5M | -45183.6% |
| 2025 | $11K | 0% | −$5M | -45183.6% |
| 2024 | $11K | 0% | −$5M | -45183.6% |
| 2023 | $11K | 0% | ||
| 2022 | $11K | 0% | ||
| 2021 | $11K | 0% | ||
| 2020 | $11K | — |
Growth signals
Xenothera website traffic
Latest recorded traffic for Xenothera is 960 monthly website visits, up 45.5% over the last three months. Xenothera's team declined 8% over the past year.
Comparisons
Xenothera compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Xenothera's talent
Source: Dealroom Talent Intelligence.
Investors
12 investors on Xenothera's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Xenothera has talent and traffic
team presence
In the news
Latest news about Xenothera
Recent press, funding announcements, and product moves mentioning Xenothera — open to read from the original sources.
Market sentiment
What the market is saying about Xenothera
An AI-synthesized read of the highest-engagement posts about Xenothera on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xenothera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.